Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thomson Medical GroupFRA:3H5 EV-to-EBIT is 91.23 as of Aug. 27, 2026, which is 81% above its 10-year median of 50.39. The stock has 6 warning signs investors should review. Among 480 Healthcare Providers & Services companies, Thomson Medical Group ranks worse than 95.83% on this metric.
The historical rank and industry rank for Thomson Medical Group's EV-to-EBIT or its related term are showing as below:
FRA:3H5'
s EV-to-EBIT Range Over the Past 10 Years
Min: -23.76 Med: 50.39 Max: 153.93
Current: 153.93
During the past 13 years, the highest EV-to-EBIT of Thomson Medical Group was 153.93. The lowest was -23.76. And the median was 50.39.
FRA:3H5's EV-to-EBIT is ranked worse than 95.83% of 480
companies
in the Healthcare Providers & Services industry
Industry Median: 15.75
vs FRA:3H5: 153.93
Thomson Medical Group (FRA:3H5) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Thomson Medical Group's Enterprise Value for the quarter that ended in Jun. 2026 was €1,799.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Thomson Medical Group's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €18.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Thomson Medical Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thomson Medical Group EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Thomson Medical Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Thomson Medical Group's EV-to-EBIT falls into.
Thomson Medical Group's current Enterprise Value is €1,705.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Thomson Medical Group's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €18.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thomson Medical Group (FRA:3H5) has a EV-to-EBIT of 91.23 as of Aug. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Thomson Medical Group and its competitors. This is 81% above median its historical median of 50.39. According to the industry distribution chart, Thomson Medical Group ranks #460 out of 480 companies in the Healthcare Providers & Services industry, placing it in the top 95.8%.
Is Thomson Medical Group's EV-to-EBIT too high?
Thomson Medical Group's current EV-to-EBIT of 91.23 is 81% above median its 10-year median of 50.39. The Healthcare Providers & Services industry median EV-to-EBIT is 15.75. Thomson Medical Group's value of 91.23 is 479.2% above this industry median. Based on the distribution chart, Thomson Medical Group ranks #460 out of 480 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Thomson Medical Group's EV-to-EBIT compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Thomson Medical Group ranks #460 out of 480 companies for EV-to-EBIT. This places Thomson Medical Group in the lower half of its industry. The industry median EV-to-EBIT is 15.75. Thomson Medical Group's value of 91.23 is 479.2% above this benchmark. While the company's 10-year median is 50.39 vs. the industry median of 15.75, Thomson Medical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.75, based on 480 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thomson Medical Group's current EV-to-EBIT of 91.23 is 479.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Thomson Medical Group and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thomson Medical Group's current EV-to-EBIT is 91.23, which is 81% above median its own 10-year median of 50.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thomson Medical Group stock overvalued right now?
Based on GuruFocus' analysis, Thomson Medical Group (FRA:3H5) is currently considered Possible Value Trap. The stock's GF Value™ is €0.05, compared to a current price of €0.04 — trading 30% below its estimated fair value. The current EV-to-EBIT is 91.23, which is 81% above median its 10-year median of 50.39 and 479.2% above the Healthcare Providers & Services industry median of 15.75. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Thomson Medical Group (FRA:3H5), the current EV-to-EBIT is 91.23 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Thomson Medical Group Ltd is a provider of healthcare services for women and children. Its segments include Hospital services; Specialised services and Investment holdings. It generates maximum revenue from the Specialised services segment. The specialised services segment includes services provided by fertility clinics, paediatric centres, cancer centre, cardiology centre, Chinese medicine, specialist skin centre and a pre-natal and clinical diagnostic laboratory and project-related services such as managing vaccination centres, COVID-19 Treatment Facilities and Transitional Care Facilities. It also includes a consumer business segment, comprising products and services. Geographically, it derives a majority of its revenue from Singapore.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3H5 has been successfully added to your 
